EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR-TKI which selectively inhibits both EGFR sensitizing mutations and EGFR T790M resistance mutations, had significantly greater efficacy than platinum-based doublet chemotherapy in T790M-positive advanced NSCLC patients who had progressed during first-line EGFR-TKI therapy13.